Skip to Main Content

Advertisement

Skip Nav Destination

Therapeutic Research and Development

Translational studies that investigate molecular targets, lead compounds, and experimental therapies in a preclinical setting

Latest in Therapeutic Research and Development
Sanja Karovic, Erik Dvergsten et al.
The Centers for Medicare & Medicaid Services Hospital Outpatient Quality Reporting Program’s OP-35 rule penalizes health systems that have a higher-than-expected rate of emergency department (ED) visits or inpatient admissions for 10 potentially preventable conditions within 30 days of receiving chemotherapy. ...
Olga Zamulko, Vidhya Karivedu et al.
Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) portends a poor prognosis. DNA pathway repair mutations in HNSCC are associated with higher tumor mutational burden rates and immune checkpoint inhibitor response. PARP inhibitors (PARPi) induce ssDNA breaks and are efficacious in cancers with DNA ...
F. Scott Heinemann, Paul D. Gershon
Resistance to chemotherapy is a critical challenge in triple negative breast cancer (TNBC). In this study, the proteomes of pretreatment core biopsy samples from 16 TNBC patients with differential response to neoadjuvant chemotherapy (NAC) were analyzed by nanoLC-MS/MS to identify biomarkers of intrinsic chemotherapy ...
Stacia L. Koppenhafer, Elizabeth L. Geary et al.
Histone deacetylases (HDAC) regulate diverse pathways in cancer cells. Previously, we identified that Ewing sarcoma tumors, which are caused by a translocation between the EWSR1 and FLI1 genes (EWS::FLI1), are sensitive to drugs that target DNA replication, including the RRM1 and RRM2 subunits of ribonucleotide reductase ...
Simbarashe Mazambani, Seong-Ho Park et al.
Head and neck squamous cell carcinoma (HNSCC) remains a clinically challenging malignancy with limited targeted therapy options and poor patient outcomes. Thus, identifying unique dependencies, including HNSCC-specific metabolic reprogramming, is imperative for improving treatment strategies for this disease. In this ...
Qingzhu Wang, Eric E. Irons et al.
Cisplatin remains a cornerstone chemotherapy for many solid tumors but is limited by dose-limiting toxicities, including nephrotoxicity, peripheral neuropathy, and ototoxicity — the latter of which disproportionately affects pediatric patients and lacks effective prevention strategies. Although therapeutic approaches to ...
Francisco J. Roa, Maria Roubelakis et al.
Cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy is the main treatment for muscle-invasive bladder cancer (MIBC). However, low survival rates highlight the necessity for new therapeutic strategies. Drug repurposing has emerged as a promising approach in cancer treatment, with various studies ...
Takuma Yoshimura, Takashi Kamatani et al.
There are currently no effective treatments available for clear cell ovarian cancer (CCC). In this study, we aimed to identify effective drugs for CCC through high-throughput drug screening (HTDS) using ovarian cancer organoids and determine novel therapeutic targets based on the biological characteristics of CCC through ...
Kentaro Sawada, Riu Yamashita et al.
Although the gut microbiome is associated with cancer development and progression, little is known about the effects of the gut microbiome landscape and the efficacy of immune checkpoint inhibitors (ICI) across cancer types. We investigated the association between the microbiome, clinical features, and ICI efficacy across ...

Topics in Therapeutic Research and Development

or Create an Account

Close Modal
Close Modal